Venita Chandra News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Venita chandra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Venita Chandra Today - Breaking & Trending Today

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD). ....

United States , Scott Kinlay , Lee Kirksey , Shipra Arya , Erica Secemsky , Maya Serhal , Sahers Sabri , Heather Gornik , Lori Byrd , Herbertd Aronow , Thomas Sd Getchius , Philipp Goodney , Esther Sh Kim , Connien Hess , J Antonio Guti , Johnn Evans , Lawrenceb Sadwin , Luke Packard Brewster , Douglase Drachman , Mehdih Shishehbor , Luker Wilkins , Jonathank Ehrman , Venita Chandra , Debra Kohlman Trigoboff , Vascular Endovascular Surgery Society , Society For Vascular Surgery ,

Cagent Vascular Announces PRELUDE-BTK Study Results Presented at LINC Symposium: Confirms Serranator Device Novel Mechanism of Action


Press release content from Business Wire. The AP news staff was not involved in its creation.
Cagent Vascular Announces PRELUDE-BTK Study Results Presented at LINC Symposium: Confirms Serranator Device Novel Mechanism of Action
February 1, 2021 GMT
WAYNE, Pa. (BUSINESS WIRE) Feb 1, 2021
Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this year’s LINC Symposium on January 29th. The PRELUDE-BTK Study, was a prospective, single-arm, multi-center feasibility study to show the safety and efficacy of Serration Angioplasty. The study was led by co-Principal Investigators, Drs. Andrew Holden (Auckland, New Zealand), who presented the data, and Michael Lichtenberg (Arnsberg, Germany). Four other centers from Europe participated in the trial which included 30-day and 6-month follow up. ....

United States , New Zealand , Michael Lichtenberg , Venita Chandra , Lauren Pfeiffer , Michael Lichtenberg Arnsberg , Carola Burns , Peter Schneider , Carol Burns , Robert Giasolli , Technology Officer , Stanford University , Principal Investigators , Andrew Holden , Balloon Catheter , Peripheral Artery Disease , Serious Adverse Events , Cagent Vascular , Vascular Surgeon , Chief Medical Officer , Chief Technology , Business Wire , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜீலாந்து , மைக்கேல் லிச்சன்பெர்க் , வேணித்த சந்திரா ,